Summary:
– Insilico Medicine has completed a $110 million financing round to further develop its AI-driven drug discovery platform.
– Rentosertib, a potential treatment for Idiopathic Pulmonary Fibrosis (IPF), targets Traf2- and NCK-interacting kinase (TNIK) crucial for fibrosis development.
– Insilico is utilizing artificial intelligence to accelerate drug development and enhance its drug pipeline progress.
Author’s Take:
Insilico Medicine secures significant funding to advance its AI-powered drug discovery platform, with a focus on developing Rentosertib as a promising treatment for IPF by targeting TNIK. By harnessing the power of artificial intelligence, Insilico is poised to revolutionize the drug discovery process and potentially bring innovative treatments to market faster.
Click here for the original article.